Faith L.  Charles net worth and biography

Faith Charles Biography and Net Worth

Director of Abeona Therapeutics

Ms. Charles is a corporate transactions and securities partner at Thompson Hine with 30 years of legal experience. She leads Thompson Hine’s Life Sciences practice, advising public and emerging biotech and pharmaceutical companies in the U.S. and internationally. Ms. Charles negotiates complex private and public financing transactions, mergers and acquisitions, licensing transactions and strategic collaborations. She serves as outside counsel to a myriad of life sciences companies and is known in the industry as an astute business advisor, providing valuable insights into capital markets, corporate governance and strategic development.

Ms. Charles serves on the Board of Directors of Entera Bio (Nasdaq:ENTX) as a member of the Audit Committee and Chair of the Compensation Committee. She also serves on the Board of Directors of several private life science companies. Ms. Charles founded the Women in Bio Metro New York chapter and chaired the chapter for five years. She currently serves on the national board of Women in Bio. Ms. Charles is also a member of the board of Gilda's Club New York City. She has been recognized as a Life Sciences Star by Euromoney’s LMG Life Sciences, has been named a BTI Client Service All-Star, and was named by Crain’s New York Business to the list of 2020 Notable Women in the Law. Ms. Charles holds a J.D degree from The George Washington University Law School and a B.A. in Psychology from Barnard College, Columbia University. Ms. Charles is a graduate of Women in Bio's Boardroom Ready Program, an Executive Education Program taught by The George Washington University School of Business.

What is Faith L. Charles' net worth?

The estimated net worth of Faith L. Charles is at least $677.39 thousand as of July 9th, 2025. Charles owns 139,094 shares of Abeona Therapeutics stock worth more than $677,388 as of December 4th. This net worth approximation does not reflect any other investments that Charles may own. Learn More about Faith L. Charles' net worth.

How do I contact Faith L. Charles?

The corporate mailing address for Charles and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Faith L. Charles' contact information.

Has Faith L. Charles been buying or selling shares of Abeona Therapeutics?

Faith L. Charles has not been actively trading shares of Abeona Therapeutics in the last ninety days. Most recently, Faith L. Charles sold 10,738 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a transaction totalling $62,924.68. Following the completion of the sale, the director now directly owns 139,094 shares of the company's stock, valued at $815,090.84. Learn More on Faith L. Charles' trading history.

Who are Abeona Therapeutics' active insiders?

Abeona Therapeutics' insider roster includes Leila Alland (Director), Mark Alvino (Director), Michael Amoroso (CEO), Edward Carr (CAO), Faith Charles (Director), Brendan O'Malley (SVP), Vishwas Seshadri (CEO), Christine Silverstein (Director), Joseph Vazzano (CFO), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.

Are insiders buying or selling shares of Abeona Therapeutics?

During the last twelve months, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 351,238 shares worth more than $2,047,717.92. The most recent insider tranaction occured on November, 13th when Director Mark Alvino sold 15,000 shares worth more than $71,100.00. Insiders at Abeona Therapeutics own 6.9% of the company. Learn More about insider trades at Abeona Therapeutics.

Information on this page was last updated on 11/13/2025.

Faith L. Charles Insider Trading History at Abeona Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/9/2025Sell10,738$5.86$62,924.68139,094View SEC Filing Icon  
4/26/2024Buy7,550$3.28$24,764.0078,323View SEC Filing Icon  
See Full Table

Faith L. Charles Buying and Selling Activity at Abeona Therapeutics

This chart shows Faith L Charles's buying and selling at Abeona Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Abeona Therapeutics Company Overview

Abeona Therapeutics logo
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
Read More

Today's Range

Now: $4.87
Low: $4.69
High: $4.92

50 Day Range

MA: $4.99
Low: $4.17
High: $5.66

2 Week Range

Now: $4.87
Low: $3.93
High: $7.54

Volume

954,439 shs

Average Volume

2,466,979 shs

Market Capitalization

$263.91 million

P/E Ratio

3.96

Dividend Yield

N/A

Beta

1.12